Larvol Delta - 23andMe-Therapeutics-Announces-Positive-Preliminary-Phase-2-Safety-and-Efcacy-Results-for-23ME00610-targeting-CD200R1-at-the-2024-ASCO-Annual-Meeting

23ME-00610 - 23andMe

https://www.globenewswire.com/news-release/2024/06/03/2892172/0/en/23andMe-Therapeutics-Announces-Positive-Preliminary-Phase-2-Safety-and-Efficacy-Results-for-23ME-00610-targeting-CD200R1-at-the-2024-ASCO-Annual-Meeting.html

Jun 3, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next